Analysts’ Ratings for Sarepta Therapeutics and Peers in April

By

Updated

Company overview

Sarepta Therapeutics (SRPT) is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics, gene therapy, and other genetic approaches for treating rare neuromuscular diseases. Its first commercial product is Exondys 51 for the treatment of Duchenne muscular dystrophy (or DMD) in patients with confirmed DMD gene mutation.

Analysts’ recommendations

Of the 19 analysts covering Sarepta Therapeutics in April 2018, six analysts gave the stock a “strong buy” rating, 11 analysts gave it a “buy” rating, and two analysts gave it a “hold” rating. The mean rating for the stock is ~1.8 with a target price of \$88.47.

Peer ratings

Of the 22 analysts covering Pfizer (PFE) in April 2018, two analysts gave the stock a “strong buy” rating, and nine analysts gave it a “buy” rating. Nine analysts gave Pfizer a “hold” rating, and two analysts gave it a “strong sell” rating. The mean rating for the stock is ~2.6 with a target price of \$40.11.

Of the eight analysts covering Tetraphase Pharmaceuticals (TTPH) in April 2018, one analyst gave the stock a “strong buy” rating, six analysts gave it a “buy” rating, and one analyst gave the stock a “hold” rating. The mean rating for the stock is 2.0 with a target price of \$7.00.

Of the 20 analysts covering Spark Therapeutics (ONCE) in April 2018, four analysts gave the stock a “strong buy” rating, and ten analysts gave it a “buy” rating. Five analysts gave the stock a “hold” rating, and one analyst gave it a “strong sell” rating. The mean rating for the stock is 2.2 with a target price of \$70.05.

In the next part of this series, we’ll take a look at Sarepta Therapeutics’ product pipeline.